mOPV1 (monovalent oral poliovirus vaccine type 1) / Panacea Biotec, Bio Farma Indonesia - LARVOL DELTA

Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial. (PubMed, Lancet Infect Dis) - P1 | "nOPV1 and nOPV3 were well tolerated and showed similar immunogenicity and shedding profiles to mOPV1 and mOPV3, respectively, supporting progression of these vaccine candidates to phase 2 studies."

Journal • P1 data • Fatigue • Infectious Disease • Musculoskeletal Pain • Pain

Genome structure and diversity of a novel ophio-like virus that infects the phytopathogenic fungus Rhizoctonia solani. (PubMed, Arch Virol) - "The RdRp of RsMOPV1 contains five typical RdRp motifs. Phylogenetic analysis demonstrated that RsMOPV1 clusters with members of the previously proposed genus "Mycoophiovirus"."

Journal • Infectious Disease

Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh (clinicaltrials.gov) - P2 | N=2012 | Recruiting | Sponsor: PATH | Trial completion date: Feb 2025 ➔ May 2026 | Trial primary completion date: Feb 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Infectious Disease

The Immunogenicity of Monovalent Oral Poliovirus Vaccine Type 1 (mOPV1) and Inactivated Poliovirus Vaccine (IPV) in the EPI Schedule of India. (PubMed, Vaccines (Basel)) - "This study shows the high efficacy of different polio vaccines for serotype 1 in all three schedules. The type 1 seroconversion rate of mOPV1 is non-inferior to bOPV. All the vaccines provide high type-specific immunogenicity. The program can adopt the use of different vaccines or schedules depending on the epidemiology from time to time."

Journal • Infectious Disease

Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh (clinicaltrials.gov) - P2 | N=1683 | Recruiting | Sponsor: PATH | Trial completion date: Jun 2024 ➔ Feb 2025 | Trial primary completion date: Jun 2024 ➔ Feb 2025

Trial completion date • Trial primary completion date • Infectious Disease

Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial. (PubMed, Vaccine) - P4 | "Given with the second mOPV1 dose, fIPV improved intestinal immunity but not humoral immunity. One mOPV1 dose induced higher humoral and intestinal immunity than bOPV."

Journal

Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh (clinicaltrials.gov) - P2 | N=1683 | Recruiting | Sponsor: PATH | Enrolling by invitation ➔ Recruiting

Enrollment status • Infectious Disease

Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh (clinicaltrials.gov) - P2 | N=1683 | Enrolling by invitation | Sponsor: PATH | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Infectious Disease

Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines (clinicaltrials.gov) - P1 | N=205 | Completed | Sponsor: PATH | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease